Topical Category Descriptions



A. Antimicrobial Pharmacokinetics, Pharmacodynamics and General Pharmacology

A1. Antimicrobial Pharmacokinetics
Relevant pharmacokinetic studies (including absorption, distribution, metabolism and elimination) of new antibacterials, antivirals, anti-HIV agents, antifungals and other anti-infectives (post-US IND) will be considered if they have not been previously reported or if they reflect unique observations. Studies on drug-drug interactions and the epidemiology, pathogenesis, and prevention of drug toxicities are encouraged.

Studies examining the penetration of antimicrobials into normal tissues or sites that are rarely infected are discouraged unless they report a unique, clinically relevant observation. Pharmacokinetic studies limited to animals are also discouraged unless they provide findings relevant to humans or to experimental chemotherapy.

A2. Antimicrobial Pharmacodynamics
In vitro pharmacodynamic studies (e.g., post-antibiotic effects, sub-MIC effects) and those performed in humans, animals and in vitro models will be considered if they provide new information. The Program Committee is especially interested in studies correlating pharmacokinetic/pharmacodynamic (PK/PD) indices (e.g., time above MIC, peak/MIC ratio, AUC/MIC ratio) with therapeutic efficacy.

Since large numbers of pharmacodynamic studies in animals and in vitro models are submitted to ICAAC, preference will be given to studies that include multiple organisms and/or multiple drugs, including established agents as controls. For animal studies, the dosages used and the drug's pharmacokinetics should be provided. The concentrations obtained in in vitro models should reflect those likely to be obtained in humans. Protein binding effects must be considered. Monte-Carlo simulation studies will only be considered if full population PK analysis has been performed and incorporated in the analysis.

B. Clinical, Translational, and Basic Science Research on Mechanisms of Microbial Pathogenesis and Host Response

Abstracts reporting results of studies that investigate the mechanisms by which 1) microbes cause damage and disease; 2) hosts respond to pathogens; and 3) therapies, including antimicrobial agents and immunomodulators, affect host-pathogen interactions are welcome. For therapeutic studies, the focus should be on approved agents or those that have advanced past Phase I testing.

C. Antibacterials: Mechanisms of Action, Resistance, Surveillance and Typing, and Molecular Epidemiology.

Abstracts are encouraged in all areas of mechanisms of action and mechanisms of resistance to antibacterial agents, including studies of genetic elements causing or regulating resistance. Studies related to surveillance and molecular epidemiology of antibiotic-resistant bacteria and resistance genes are also appropriate. Other abstracts considered include novel assays and methods for detection of resistance genes and mechanisms of resistance, as well as analyses and comparisons of typing methods for differentiating bacterial strains. Abstracts that provide surveillance data on emergence or reductions in resistance of major public health importance are welcome.

Abstracts dealing with viral or fungal resistance should be submitted to categories "H", "M" or "V", as appropriate. Methods for screening of resistance phenotypes would fall under category "D". Clinical epidemiology studies of factors contributing to resistance,and studies of the effects of modalities enacted to decrease resistance in patient populations should be submitted to category "K". Resistance surveys for sexually transmitted microorganims should be submitted to category “L”.

D. Laboratory Tests for Diagnosing Infections; Methods for Antibacterial Susceptibility Testing

Abstracts presenting clinically relevant studies of recovery, enumeration, or characterization of microorganisms from clinical specimens will be considered. Innovative methods and instrumentation, particularly techniques which are faster or produce clinically useful data, are of interest. Repetitive trials or comparisons of instruments or methods are acceptable only if different from those previously published or if additional conclusions are reported. Laboratory diagnostic approaches for newly recognized infectious diseases, as well as cost effectiveness, outcomes-based and clinical integration studies are encouraged. Studies of in vitro susceptibility tests addressing new methods, clinical relevance, and/or development of interpretive criteria are appropriate. MIC data and/or time-kill studies using antimicrobial agents entering clinical trials and/or recently introduced into clinical practice and in vitro studies using clinically-relevant drug combinations are welcome. MIC studies involving multiple institutions and a large number of isolates are preferred. Studies defining activities of antimicrobial agents against select or well-defined groups of organisms will be judged based on clinical relevance.

E. Experimental Therapeutics

Abstracts reporting novel approaches to the treatment of bacterial infections in both animal and human studies will be considered. Animal models of infection that mimic human disease processes are encouraged. These include models that go beyond the standard thigh and lung models used in PK/PD studies, novel models for a specialized type of infection and infections with an organism that has not previously been established in an animal model. Studies of human clinical trials for marketed antibiotics or novel agents investigating a new indication or dosing regimen will also be considered. These trials should be research-based studies that are not intended to be part of a registration package.

F. New Antimicrobial Agents (i.e. pre-US IND or prior to the start of any clinical therapeutic studies) and New Research Technologies

ICAAC provides the premier forum for the introduction of new antimicrobial agents and novel approaches for their identification and characterization. Abstracts dealing with the isolation, purification, and characterization of new antimicrobial agents and their chemistry, structure-activity relationships, mechanisms of action, microbiological activity, PK/PD in animals and development studies through to Phase 3 clinical data (at a stage equivalent to USA New Drug Application) are given priority consideration. These abstracts should contain data encompassing, where relevant: structure of the compound, producing organism, purification steps, physical-chemical characterization, brief synthetic schemes, structures, MICs, and ED50s describing the new compounds and their properties. The Program Committee requires that structures of new agents be presented in at least one poster in the session and requests that the name or compound class of the new agent be included in the title of the abstract.

Abstracts describing the use and output of new technology platforms, including development of animal models related to novel compounds, that are applicable in the early stages of anti-infective drug discovery are welcomed. Representative structures of agents identified or characterized using the new technologies should be presented.

G. Pediatric Infections

Abstracts relating to aspects of pediatric infections, including pathogenesis, epidemiology, treatment, outcome, and clinical trials are invited. Both in vitro and in vivo data are welcome. Submissions pertaining to infection control in children or pediatric institutions should be submitted to category K.

H. HIV/AIDS and Other Retroviruses, Including Resistance

Abstracts on all aspects of HIV, retroviruses and complications of HIV/AIDS are appropriate. This category includes susceptibility testing methods and results, resistance, pathogenesis, epidemiology, natural history, pre-clinical studies of antiretroviral drugs (post-US IND), clinical trials and outcome research for treatment and prevention, including PK/PD studies of antiretroviral agents. Studies of co-infections in HIV (eg HCV, HBV, other agents) are encouraged, however, fungal co-infections should be submitted to Category M. Specific studies on diagnostic tools should be submitted to Category D. Abstracts will be judged on uniqueness and clinical relevance.

  • H1. HIV Epidemiology, Natural History, Pathogenesis and HIV-Related Morbidities Including Outcomes Studies
  • H2. Antiretroviral Agents for Treatment and Prevention Including Preclinical and All Phases of Clinical Trials, PK/PD and resistance
  • H3. Co-Infections in HIV (eg HCV, HBV, Other Agents)


I. Vaccines and Immunization Science

Abstracts dealing with vaccines to prevent bacterial, viral, or fungal diseases in pediatric or adult patients are welcomed. Abstracts that discuss antigen discovery or delivery, adjuvants or immunomodulators, or systems vaccinology/genetic basis of vaccine response are especially encouraged.

K. Healthcare-Associated and Surgical Infections and Clinical Epidemiology

Abstracts dealing with studies that help us better understand the burden, risk factors, epidemiology, and prevention of endemic or epidemic infections in the healthcare environment and in surgical patients are welcome. Also of interest are studies that utilize molecular epidemiological techniques to address these issues. Studies that focus on molecular epidemiology of resistant bacteria, and the epidemiology and molecular epidemiology of community-acquired infections should be submitted to category C.

L. Clinical Treatment and Outcome Trials Involving Adult Community-Acquired Infections, Including Obstetrical-Gynecological and Sexually Transmitted Infections

Abstracts on most aspects of community-acquired infections are appropriate for this category. This would include studies of the natural history, epidemiology, and molecular epidemiology, prevention, and treatment, as well as outcomes and antibacterial clinical trials of community-acquired infections in adults; results of susceptibility testing of sexually transmitted microorganisms are also appropriate.

  • L1. Community-Acquired Infections in Adults, including Clinical Trials
  • L2. Sexually-Transmitted, Urinary Tract and Obstetrics and Gynecology Infections

M. Mycology, Including Resistance and Mechanisms of Action of Antifungals

Abstracts on most aspects of medical mycology are appropriate, including diagnostic tools, susceptibility testing methods and results, mechanisms of action and resistance, pathogenesis, epidemiology, natural history, pre-clinical studies of antifungal drugs (post-US IND), and clinical trials.

P. Neglected Tropical Diseases, Parasitic Helminthic and Protozoan Infections, Malaria, Global Health, and Travel Medicine

Topics related to control and elimination of Neglected Tropical Diseases (NTDs, e.g. helminthic infections, trachoma) and other parasitic infections endemic in tropical and sub-tropical areas (e.g., malaria); national and international strategies to control NTDs; recent scientific advances that inform monitoring and evaluation of public health interventions and treatment of individual patients with parasitic pathogens are welcome. Studies of diagnostic tools, therapeutic mechanisms of action, drug resistance, clinical aspects, pathogenesis, epidemiology, and natural history are appropriate as are those dealing with prevention, treatment and diagnosis of health problems of travelers and refugee medicine.

T. Transplantation Infectious Diseases

Abstracts related to infections in solid organ transplantation, hematopoietic stem cell transplantation, and other populations with pharmacologically-induced immunosuppression are welcome. This category includes clinical studies involving these populations, diagnostic issues, donor-derived infections, immunosuppression-related infections, and related treatments. Abstracts related to infection control should be submitted to Category K.

V. Virology (Non-HIV), including Hepatitis

Abstracts on most aspects of non-HIV virology, including hepatitis, are appropriate, including pathogenesis, epidemiology, natural history, pre-clinical studies of antiviral drugs (post-US IND), mechanisms of antiviral action and resistance, animal models, and clinical trials.